[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Gesynta Pharma AB\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100612983","phase-2-a-phase-2-trial-to-investigate-efficacy-and-safety-of-vipoglanstat-in-women-with-endometriosis-100612983",false,"NCT07260669","A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis","A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of 2 Doses of Vipoglanstat in Patients With Moderate to Severe Endometriosis-related Pain - the NOVA Trial","NOVA","Inclusion Criteria:\n\n* Premenopausal females 18 to \\\u003C 45 years of age at the time of Visit 1.\n* Endometriosis diagnosis confirmed and documented within the last 10 years prior to Visit 1 or during Visit based on:\n\n  * Surgical (via direct visualization or biopsy verified) or\n  * Imaging (ie, endometriotic lesion(s) detected by transvaginal sonography or magnetic resonance imaging \\[MRI\\].\n* History of NMPP significantly affecting daily life confirmed at Visit 1.\n* The participant reports moderate, severe, or very severe pain during non-menstrual days in the month prior to Visit 2, based on patient global assessment NMPP.\n\nExclusion Criteria:\n\n* Chronic pelvic pain that is not judged to be primarily related to endometriosis (eg, chronic pelvic infection, interstitial cystitis, nerve entrapments or neuropathies, non-endometriosis-related pelvic adhesive disease, persistent symptomatic ovarian cyst \\[eg, dermoid\\], posttubal ligation, symptomatic hydrosalpinx, and vaginismus).\n* Has had more than 2 surgical procedures for endometriosis.","FEMALE","18 Years","44 Years",{"count":21,"type":22},190,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The main objective of the trial is to evaluate the efficacy of vipoglanstat on endometriosis-related non-menstrual pelvic pain (NMPP).",[28],"Endometriosis",[30,31,32],"Non-menstrual pelvic pain","Dysmenorrhea","Pelvic pain","RECRUITING","2026-09-10",{"date":36,"type":37},"2026-09-11","ACTUAL",{"date":39,"type":37},"2025-10-15",{"date":41,"type":22},"2027-06",{"name":43,"class":44},"Gesynta Pharma AB","INDUSTRY",44,""]